Head and Neck Neuroendocrine Carcinoma — Trials

Head and Neck Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 27
Recruiting: 10
Ph III recruiting: 1
Growth YoY: —
Industry share: 30%
Top sponsor: Eli Lilly and Company
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02831179	Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor	withdrawn	Phase 1	0	Vanderbilt-Ingram Cancer CenterOTHER	0	Sep 28, 2017	clinicaltrials

Data updated 22 days agoSource updated Sep 28, 2017source: clinicaltrials